Last reviewed · How we verify

Itching of ear — Treatment Landscape & Competitive Intelligence

Itching of ear (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Itching of ear, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Galzin ZINC ACETATE Eton zinc acetate 1980-01-01
Cortef hydrocortisone Generic (originally Merck/Upjohn) Corticosteroid [EPC] Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible 1952-01-01
Cortisol Cortisol University of Zurich Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 3 drugs in Itching of ear
  2. Eton · 1 drug in Itching of ear
  3. Generic (originally Merck/Upjohn) · 1 drug in Itching of ear
  4. University of Zurich · 1 drug in Itching of ear

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Itching of ear:

Cite this brief

Drug Landscape (2026). Itching of ear — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/itching-of-ear. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing